GB2471970A - Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide - Google Patents
Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide Download PDFInfo
- Publication number
- GB2471970A GB2471970A GB1018110A GB201018110A GB2471970A GB 2471970 A GB2471970 A GB 2471970A GB 1018110 A GB1018110 A GB 1018110A GB 201018110 A GB201018110 A GB 201018110A GB 2471970 A GB2471970 A GB 2471970A
- Authority
- GB
- United Kingdom
- Prior art keywords
- amlodipine
- olmesartan medoxomil
- concentration
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 229940051540 amlodipine and hydrochlorothiazide olmesartan medoxomil Drugs 0.000 title 1
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 claims abstract description 45
- 229960001199 olmesartan medoxomil Drugs 0.000 claims abstract description 44
- 239000007909 solid dosage form Substances 0.000 claims abstract description 44
- 229960000528 amlodipine Drugs 0.000 claims abstract description 36
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 claims abstract description 34
- 239000012535 impurity Substances 0.000 claims abstract description 18
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims abstract description 17
- 206010020772 Hypertension Diseases 0.000 claims abstract description 16
- 229960002003 hydrochlorothiazide Drugs 0.000 claims abstract description 15
- AAEQXEDPVFIFDK-UHFFFAOYSA-N 3-(4-fluorobenzoyl)-2-(2-methylpropanoyl)-n,3-diphenyloxirane-2-carboxamide Chemical compound C=1C=CC=CC=1NC(=O)C1(C(=O)C(C)C)OC1(C=1C=CC=CC=1)C(=O)C1=CC=C(F)C=C1 AAEQXEDPVFIFDK-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 238000011321 prophylaxis Methods 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims description 54
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 12
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 4
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 abstract description 54
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract description 22
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 abstract description 17
- 235000019359 magnesium stearate Nutrition 0.000 abstract description 11
- 229920000881 Modified starch Polymers 0.000 abstract description 10
- 229960004005 amlodipine besylate Drugs 0.000 abstract description 10
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract description 8
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract description 8
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 abstract description 7
- 229960001681 croscarmellose sodium Drugs 0.000 abstract description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 7
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract description 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract description 2
- 239000000480 calcium channel blocker Substances 0.000 abstract description 2
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 41
- 238000009472 formulation Methods 0.000 description 29
- 229940043092 olmesartan medoxomil and amlodipine Drugs 0.000 description 24
- 238000000034 method Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- 239000007888 film coating Substances 0.000 description 13
- 238000009501 film coating Methods 0.000 description 13
- 235000000346 sugar Nutrition 0.000 description 13
- -1 2,3 -dihydroxy-2-butenyl Chemical group 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- 239000002585 base Substances 0.000 description 10
- 229940036132 norvasc Drugs 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 150000008163 sugars Chemical class 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229940000425 combination drug Drugs 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000005480 Olmesartan Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229920001903 high density polyethylene Polymers 0.000 description 4
- 239000004700 high-density polyethylene Substances 0.000 description 4
- 229960005117 olmesartan Drugs 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004373 Pullulan Substances 0.000 description 3
- 229920001218 Pullulan Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000011132 calcium sulphate Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 229960001021 lactose monohydrate Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229960003511 macrogol Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 235000019423 pullulan Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 238000009506 drug dissolution testing Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal Chemical compound OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000005434 MCC/mannitol excipient Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940121792 Thiazide diuretic Drugs 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940055053 benicar Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composition comprising olmesartan medoxomil (angiotensin II receptor antagonist), amlodipine, preferably, amlodipine besylate (calcium channel blocker) and hydrochlorothiazide (diuretic). Preferably the composition is a solid dosage form, in particular a tablet and has less than 7.3% concentration (w/w) of total impurities. The composition preferably has less than 2.5% concentration (w/w) of 4- (1-hydroxy-1-methylethyl)-2-propyl -1-[[2'-(1H-tetrazol-5-y1)biphenyl-4-y1]methyl]-1H-imidazol-5-carboxylic acid (RNH-6270), and/or less than 0.4% concentration (w/w) of 3-ethyl-5-methyl-2-[(2-alninoethocy)methyl]-4-(2-chlorophenyl)-6-methylpyridine-3,5-dicarboxylate (impurity D). Preferably the composition is for use in the treatment or prophylaxis of hypertension and comprises 20 to 40 mg of olmesartan medoxomil, 5 to 10 mg of amlodipine and 12.5 to 25 mg of hydrochlorothiazide. Typically the composition comprises (in mg) olmesartan medoxomil (40), amlodipine (13.89), hydrochlorothiazide (12.5), pregelatinized starch (105), silicified microcrystalline cellulose (112.41), croscarmellose sodium (15) and magnesium stearate (1.2).
Description
DESCRIPTION
Solid dosage form of olmesartan medoxomil, amlodipine and hydrochiorothiazide
[Technical Field of the Invention]
The present invention relates to a solid dosage form comprising olmesartan medoxomil and amlodipine and further comprising hydrochlorothiazide.
[Background of the Invention]
Olmesartan medoxomil is an angiotensin II receptor antagonist developed for the treatment of hypertension and other medical indications as disclosed in USP 5,616,599. Its chemical name is 2,3 -dihydroxy-2-butenyl 4-( 1 -hydroxy-1 -metbylethyl)- 2-propyl-1 -[p-(o-1 Htetrazol5y1phenyl)benzYl]indZoleSc0xYinte, cyclic 2,3- carbonate or (5 -methyl-2-oxo-1,3 dioxolen4-yl)methy1 4-( 1 -hydroxy-I -methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)pheflYllPheflYl} rnethylimidazole-S -carboxylate having the following structure: CH3\ /CH3 a
I
Olmesartan medoxomil is marketed by Sankyo under the trade name of Olmetec� or Benicar�. It is available as oral tablets in strengths of 5 mg, 10 mg, 20 mg and 40 mg. The inactive ingredients in the Olmetec� tablets include low-substituted hydroxypropylcellulOSe, microcrystalline cellulose, lactose monohydrate, hydroxypropylcellulose and magnesium stearate.
Olmesartan medoxomil is a prodrug which, after ingestion, liberates the only active metabolite, 4-( 1 -hydroxy-1.-inethylethyl)-2-propYl-1 -[2' -(1 H-tetrazol-5 -yl)biphenyl-4-y1]methyl]lHimidazol-5-Carb0XYliC acid (RNH-6270). The chemical structure of RN}l-6270 is: H3C CH3 H3C -\N oo N. NH
N
Under acidic or basic conditions and in the presence of water, RNH-6270 is formed by hydrolysis of the ester bond of olmesartan medoxomil.
Amlodipine is a calcium channel blocker developed for the treatment of hypertension and other medical indications as disclosed in USP 4,572,909 and USP 4,879,303. Its chemical name is 3-ethyl-S chlorophenyl)-1,4dihydro6IT1ethylpYridifle3,5 -dicarboxylate, having the following structure:
CH NH2
Amlodipine is marketed by Pfizer as the monobenzenesulfonate salt, amlodipine besylate under the trade name Norvasc�. It is available as oral tablets in strengths of 2.5 mg, 5 mg and 10 mg. The inactive ingredients in the Norvasc� tablets include microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate and magnesium stearate.
WO 2006/0592 17 discloses that amlodipine is highly hygroscopic and absorbs moisture, which leads to degradation. One of the major routes of degradation is via a catalytic oxidative process, which is pH dependent. One of the major degradation products is 3 methylpyridine3,5diCarb0XYlate (Impurity D). The chemical structure of Impurity D is: CH3 ? H3C2L0 NH2 Pharmaceutical Development and Technology, vol. 9, No. 1, pp.1S-24, 2004 discloses that mixtures of lactose, basic excipients and water induce some instability in anilodipine besylate because of a Maillard reaction between the primary amino group and lactose.
As amlodipine is an unstable compound, well-directed approaches are required to formulate pharmaceutical compositions with reasonable stability.
Although WO 04/067003 and EP 1604664 disclose a medicament comprising olmesartari medoxomil and amlodipine, there is no known stable solid dosage form comprising olmesartan medoxomil and amlodipine.
[Objects of the Invention] The mechanisms of action of olmesartan medoxomil and anilodipine are believed to cooperate favorably in the treatment or prophylaxis of hypertension or diseases caused by hypertension. As this assumption becomes supported by an increasing amount of clinical data, there is an escalating need for a fixed dose combination drug comprising the active ingredients olmesartan medoxomil and amlodipine. However, both olmesartan medoxomil and amlodipine are chemical compounds that are difficult to formulate owing to stability problems of said active ingredients. Therefore, although there is a clear need for a fixed dose combination drug which combines the features of adequate drug stability and solubility with pharmacological efficacy, to achieve this a number of technical problems must be overcome. It is an object of the present invention to provide such a fixed dose combination drug.
There are various types of solid dosage forms that could be considered, but it cannot be predicted which of these dosage forms combines product stability, solubility and pharmacological efficacy in the best manner. Generally, a fixed-dose combination of drugs intended for instant release is prepared by making a powder mixture of a co-granulate of the two active ingredients with the necessary excipients, by keeping the basic formulation of one of the corresponding mono-drug preparations and simply adding the second drug component.
With a combination of olmesartan medoxomil and amlodipine, this approach does not appear feasible due to the incompatibility of amlodipine with components of the conventional olmesartart medoxomil formulations. When an Olmetec� based formulation is used for the fixed dose combination drug, degradation products appear in the dosage form because of a Maillard reaction between amlodipine and lactose in the formulation. When a Norvasc� based formulation is used, on the other hand, solubility and bioavailability of the olmesartan medoxomil decreases. Furthermore, the preparations of olmesartan medoxomil and amlodipine currently on the market have several drawbacks. The weights of the known Olmetec� tablets and Norvasc� tablets are relatively high (218 mg and 432 mg in Olmetec� tablets, 200 mg and 400 mg in Norvasc� tablets, respectively). Due to the large amount of the excipients present in the formulations, the tablet size for both the Olmetec� and Norvasc� formulations is relatively large, and such large tablets are difficult to swallow, especially for aged patients. The present invention is directed towards the preparation of a stable solid dosage form comprising olmesartan medoxomil and amlodipine which overcomes the aforementioned problems.
[Summary of the Inventioni
The object of the present invention is to provide a solid dosage form comprising olmesartan medoxomil and arnlodipine or a pharmacologically acceptable salt thereof with improved stability of the active ingredients and reduced weight. In accordance with the present invention, problems associated with the preparation of a solid dosage form comprising olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof can best be handled by means of the preparation of formulations that are substantially free of reducing sugar in the formulation.
The present invention provides solid dosage forms comprising olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof, which are characterized by having less than 2.5 % concentration (w/w) of RNH-6270, less than 0.4 % concentration (w/w) of Impurity D and less than 5.1 % concentration (wlw) of total impurities and by being substantially free of reducing sugar (particularly a dosage form for the prophylaxis or treatment of hypertension), the use of olmesartarl medoxomil and amlodipine or a pharmacologically acceptable salt thereof to manufacture the aforementioned solid dosage form (particularly a dosage form for the prophylaxis or treatment of hypertension), a method for preventing or treating a disease (particularly hypertension) in which the aforementioned solid dosage form comprising pharmacologically effective amounts of olmesartan rnedoxoniil and amlodipine or a pharmacologically acceptable salt thereof is administered to warm-blooded animals (particularly humans) and a use of a solid dosage form comprising olmesartan medoxomil and amlodipirie or a pharmacologically acceptable salt thereof in the manufacture of a medicament for preventing or treating a disease (particularly hypertension). The solid dosage form of the invention further comprises the thiazide diuretic hydrochiorothiazide, which has the following structural formula: H2NO2S Hydrochiorothiazide Specifically, the present invention provides: (1) a pharmaceutical composition comprising olmesartan medoxomil, amlodipine or a pharmacologicallY acceptable salt thereof, and hydrochlorothiaZide or a pharmacologically acceptable salt thereof; (2) a pharmaceutical composition according to (1), wherein the composition is a solid dosage form; (3) a pharmaceutical composition according to (1) or (2), wherein the composition has less than 7.3 % concentration (w/w) of total impurities; (4) a pharmaceutical composition according to any one of (1) to (3), wherein the composition has less than 5.1 % concentration (w/w) of total impurities; (5) a pharmaceutical composition according to any one of (1) to (4), wherein the composition has less than 2.5 % concentration (w/w) of 4(1hydroxy-1-methYlCthYD-2-propyl-1 -[2' -(1 HtetrazoI5Yl)biPhe11Yl4Yl1methYlH HimidazoI5Carb0xYliC acid (RNH-6270); (6) a pharmaceutical composition according to any one of (1) to (4), wherein the composition has less than 0.4 % concentration (wlw) of 3ethyl-5-methy1-2-[(2 ,5 -dicarboxylate (Impurity D); (7) a pharmaceutical composition according to any one of (1) to (6) wherein the amlodipine is present in the form of its besylate salt; (8) a pharmaceutical composition according to any one of (1) to (7), wherein the composition is a solid dosage form that comprises a tablet; (9) a pharmaceutical composition according to any one of (1) to (8), comprising 20 to 40 mg of olmesartan medoxomil; (10) a pharmaceutical composition according to any one of(1) to (9), comprising 5 to mg of amlodipine or a pharmacologically acceptable salt of amlodipine equivalent to to 10 mg of amlodipine; (11) a pharmaceutical composition according to any one of(1) to (10), comprising 12.5 to 25 mg of hydrochiorothiazide or a pharmacologically acceptable salt of hydrochlorothiazide equivalent to 12.5 to 25 mg of hydrochlorothiazide; (12) use of a pharmaceutical composition according to any one of (1) to (11) in the manufacture of a medicament for the treatment or prophylaxis of hypertension; and (13) a pharmaceutical composition according to any one of(1) to (11) for use in the treatment or prophylaxis of hypertension.
[Brief Description of Drawings]
Fig. 1 shows the results for the concentration of Impurity D and RNH-6270 as measured in Test Example 1 for Olmetec�, Norvasc�, the formulation of Example 1 and the formulation of Reference Example 1.
Fig. 2 shows the results for the rates of dissolution for the formulation of Example 1 and the formulation of Reference Example 1 as measured in Test Example 2.
[Detailed Description of the Invention]
The solid dosage form of the present invention contains olmesartan medoxomil and amlodipine or a pharmacologically acceptable acid salt thereof as its active ingredients, and further contains hydrochlorothiaZide or a pharmacologically acceptable acid salt thereof.
Olmesartan medoxomil can easily be produced according to the methods disclosed in the art, suitable examples including the methods disclosed in US Patent No. 5,616,599.
Amlodipine can be easily produced according to the methods disclosed in the art, suitable examples including the methods disclosed in US Patent No. 4,572,909.
Amlodipine can be used as a pharmacologically acceptable acid salt thereof, such as a besylate, maleate, fumarate, camsylate, hydrochloride, hydrobromide, lactate, tartrate, citrate, mesylate, nicotinate, gluconate and the like, as well as in the form of a free base.
Of these, amlodipine besylate is preferably used.
FlydrochlorothiaZide can be easily produced according to the methods disclosed in the art, suitable examples including the methods disclosed in US Patent No. 3,025,292. The compound name of hydrochiorothiazide is 6-chloro-3,4-dihydrO-2H- 1,2,4,benzothiadiaZifl-7sUlf0nam 1,1-dioxide. The hydrochiorothiazide of this invention includes phannacologicallY acceptable salts thereof, for example, a bydrohalogenic acid salt such as hydrofluoride, hydrochloride, hydrobromide or hydroiodide; nitrate; perchiorate; sulfate; phosphate; a C1-C4 alkanesulfonic acid salt, which may be optionally substituted with a halogen atom(s) such as methanesulfonate, trifluoromethaneSUlfonate or etbanesulfonate a C6-C10 arylsulfonic acid salt, which may be optionally substituted with a C1-C4 alkyl group(s), such as benzenesulfonate or p-toluenesulfonate; a Ci-C6 aliphatic acid salt such as acetate, malate, fumarate, succinate, citrate, tartrate, oxalate or maleate; or an amino acid salt such as the glycine salt, lysine salt, alginine salt, ornitine salt, glutamic acid salt or aspartic acid salt. The preferred salts are the hydrochloride, nitrate, sulfate or phosphate and the particularly preferred salt is hydrochloride.
In one aspect of the invention, the solid dosage form has less than 2.5 % concentration (wlw), preferably less than 0.5 % concentration (wiw), and more preferably less than 0.4 % concentration (w/w) of RNH-6270. In another aspect of the invention, the solid dosage form also has less than 0.4 % concentration (w/w), preferably less than 0.3 % concentration (wlw) and more preferably less than 0.05% concentration (wlw) of Impurity D. In yet another aspect, the solid dosage form also has less than 5.1 % concentration (w/w), and preferably less than 1.5 % concentration (wlw) of total impurities.
The solid dosage form further comprises hydrochiorotbiazide or a pharmacologically acceptable salt thereof. In a preferred aspect of this triple combination solid dosage form (comprising olmesartan medoxomil, amlodipine or a pharmacologically acceptable salt thereof and hydrochiorothiaZide or a pharmacologically acceptable salt thereof), the solid dosage form has less than 2.5 % concentration (w/w), preferably less than 0.5 % concentration (wiw), and more preferably less than 0.4 % concentration (w/w) of RNH-6270. In another preferred aspect of the triple combination solid dosage form of the invention, the solid dosage form also has less than 0.4 % concentration (w/w), preferably less than 0.3 % concentration (w/w) and more preferably less than 0.05% concentration (wiw) of Impurity D. In yet another aspect, the triple combination solid dosage form also has less than 7.3 % concentration (w/w), and preferably less than 1.5 % concentration (w/w) of total impurities.
The term "stable" as used herein refers to chemical stability of olmesartan medoxoniil and/or amlodipine or a pharmacologicallY acceptable acid salt thereof in the solid dosage forms and indicates the presence of less than 2.5 % concentration (w/w) of RNH-6270 and/or less than 0.4 % concentration (w/w) of Impurity D and/or less than 5.1 % concentration (wiw) of total impurities. For solid dosage forms of the invention further comprising hydrochlorothiazide or a pharmacologically acceptable salt thereof, the term "stable" as used herein refers to chemical stability of olmesartan medoxomil andlor amlodipine or a pharmacologically acceptable acid salt thereof in the solid dosage forms and indicates the presence of less than 2.5 % concentration (w/w) of RNH-6270 and/or less than 0.4 % concentration (w/w) of Impurity D and/or less than 7.3 % concentration (w/w) of total impurities. Preferably, the stability is measured using HPLC to measure the presence of related substances after accelerated testing for three months at 40°C and 75% relative humidity on the basis of the percentage concentrations of the impurities relative to the active substances from which they are derived, e.g. a 2.5% concentration (wlw) of RNH-6270 means that at the time of measuring, the amount of RNH-6270 is 2.5% of the amount of olmesartan medoxomil as measured at the same time. This stability data is provided below in Table 1, in terms of the percent concentrations (w/w) relative to the active substances from which they are derived.
The term "total impurities" as used herein refers to the total degradation products derived from olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof. Where the solid dosage form further comprises hydrochiorothiazide or a pharmacologically acceptable salt thereof, the "total impurities" also include degradation products derived from said hydrochiorothiaZide or a pharmacologically acceptable salt thereof.
A reducing sugar is a type of sugar with an aldebyde group, which allows the sugar to act as a reducing agent, for example in a Maillard reaction or a Benedict's reaction. Examples of "reducing sugars" include, but are not limited to, lactose, glucose, fructose, glyceraldehyde, arabinose, mannose, galactose, maltose, xylose, cellobiose, mellibiose, maltotriose, and the like, as well as hydrates thereof.
The term "substantially free" as used herein refers to the use of a reducing sugar in a concentration less than is suitable for it to be used as an excipient. The solid dosage form preferably has less than 2.0% (wlw) of reducing sugars, more preferably less than 0.3% preferably less than 0.05% (w/w) reducing sugars.
The solid dosage form of the present invention can where desired additionally contain at least one further additive such as a suitable pharmacologically acceptable excipient, lubricant, binder, disintegrants, emulsifier, stabilizer, corrective or diluent.
Suitable "excipients" include, but are not limited to, either individually or in combination, organic excipients including non-reducing sugar derivatives such as sucrose, trehalose, mannitol or sorbitol; starch derivatives such as corn starch, potato starch, a-starch or dextrin; cellulose derivatives such as microcrystalline cellulose or silicified microcrystalline cellulose; gum Arabic; dextran; and pullulan, and inorganic excipients including silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, calcium silicate or magnesium metasilicate aluminate; phosphates such as dibasic calcium hydrogenphosphate or calcium hydrogen phosphate dihydrate; carbonates such as calcium carbonate; and sulfates such as calcium sulfate. Of these, silicified microcrystalline cellulose and mannitol are preferably used.
Suitable "lubricants" include, but are not limited to, either individually or in combination, stearic acid; stearic acid metal salts such as calcium stearate or magnesium stearate; talc; colloidal silica; waxes such as beeswax or spermaceti; boric acid; adipic acid; sulfates such as sodium sulfate; glycol; fumaric acid; sodium benzoate; D,L-leucine; lauryl sulfates such as sodium lauryl sulfate or magnesium lauryl sulfate; silicates such as silicic anhydride or silicate hydrate; and the aforementioned starch derivatives. Of these, magnesium stearate is preferably used.
Suitable "binders" include, but are not limited to, either individually or in combination, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, macrogol and compounds similar to the aforementioned excipientS.
Suitable "disintegrants" include, but are not limited to, either individually or in combination, cellulose derivatives such as low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, calcium carboxymethyl cellulose or internally crosslinked sodium carboxymethyl cellulose; cross-linked polyvinylpyrrolidone; and chemically modified starches/celluloses such as carboxymethyl starch, sodium carboxymethyl starch, sodium starch glycolate, pregelatinised starch or croscarmellose sodium. Of these, pregelatinised starch and croscarmellose sodium are preferably used.
Suitable "emulsifiers" include, but are not limited to, either individually or in combination, colloidal clays such as bentonite or bee gwn; metal hydroxides such as magnesium hydroxide or aluminum hydroxide; anionic surfactants such as sodium lauryl sulfate or calcium stearate; cationic surfactants such as benzalkonium chloride; and nonionic surfactants such as polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester or sucrose fatty acid ester.
Suitable "stabilizers" include, but are not limited to, either individually or in combination, para-hydroxybenzoic acid esters such as methyl paraben or propyl paraben; alcohols such as chiorobutanol, benzyl alcohol or phenyl ethyl alcohol; benzalkonium chloride; phenols such as phenol or cresol; thimerosal; dehydroacetic acid; and sorbic acid.
Suitable "correctives" include, but are not limited to, either individually or in combination, sweeteners such as sodium saccharin or aspartame; sour flavourings such as citric acid, malic acid or tartaric acid; and fragrances such as menthol, lemon or orange fragrance.
Suitable "diluents" include, but are not limited to, either individually or in combination, mannitol, sucrose, calcium sulfate, calcium phosphate, hydroxypropyl cellulose, microcrystalline cellulose, water, ethanol, polyethylene glycol, propylene glycol, glycerol, starch, polyvinylpyrrolidone, magnesium metasilicate aluminate, and mixtures thereof.
The "solid dosage form" of the present invention comprises any dosage form used by the person skilled in the art to deliver one or more pharmacologically active ingredients to a patient in a solid form. Suitable solid dosage forms will be well known to the person skilled in the art, and non-limiting examples of the solid dosage form of the present invention include tablets (including sublingual tablets and tablets that disintegrate in the mouth), capsules (including soft capsules and microcapsules), granules, pills and lozenges. Of these, tablets are most preferred.
A solid dosage form of the present invention may be produced using any commonly used method well known to a person skilled in the art of pharmaceutical formulation technology and there are no particular limitations thereon. Examples of suitable methods include those disclosed in publications such as Powder Technology and Pharmaceutical Processes [D. Chulia et al., Elsevier Science Pub. Co. (December 1, 1993)].
A tablet of the present invention can be obtained by a direct compression method. In a direct compression method, the active ingredients, together with one or more pharmacologically acceptable additives, are blended in a suitable blender, then transferred directly to a compression machine for pressing into a tablet. Other conventional methods such as wet granulation or dry granulation can also be used.
In addition, a tablet of the present invention may also be provided with at least one layer of a film coating. If a film coating is desired, any film coating apparatus of a type well known in the art can be used, and as film coating bases, suitable examples include sugar coating bases, hydrophilic film coating bases, enteric film coating bases and sustained release film coating bases.
Suitable examples of sugar coating bases include saccharose, and these can be used in combination with one or more additives such as talc, precipitated calcium carbonate, calcium phosphate, calcium sulfate, gelatin, gum Arabic, polyvinylpyrrolidone and pullulan.
Suitable examples of hydrophilic film coating bases include cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose (e.g., Opadry� OY S 38956 (white), commercially available from Colorcon, Inc.), hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose; synthetic polymers such as polyvinyl acetal diethyl aminoacetate, aminoalkyl methacrylate copolymer, polyvinylpyrrolidone, polyvinyl alcohol (e.g., Opadry� II, commercially available from Colorcon, Inc.), polyvinylalcol-polyethYlefle glycol graft-copolymers (e.g., Kollicoat� IR, commercially available from BASF) and macrogol; and polysaccharides such as pullulan. Of these, polyvinyl alcohol and macrogol are preferably used.
Suitable examples of enteric film coating bases include cellulose derivatives such as hydroxypropyl methyl cellulose, phthalate hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose and cellulose acetate pbthalate; acrylic acid derivatives such as metbacrylic acid copolyrner L, methacrylic acid copolymer LD and methacrylic acid copolymer S; and natural substances such as shellac.
Suitable examples of sustained release film coating bases include cellulose derivatives such as ethyl cellulose; and acrylic acid derivatives such as aminoalkyl methacrylate copolymer RS, ethyl acrylate-methyl methacrylate copolymer emulsion.
A mixture of two or more different coating bases such as those above may also be used in a suitable ratio. In addition, the coating films may also contain suitable pharmacologically acceptable additives such as plasticizers, excipients, lubricants, opacifying agents, colorants or antiseptics as necessary.
The doses and the dosing ratios of olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof and, where applicable, hydrochiorothiazide or a pharmacologically acceptable salt thereof, which are the active ingredients in the solid dosage form of the present invention, can be changed depending on various factors such as the activity of each of the active ingredients and the symptoms, age and body weight of the patient. Although the dosage varies depending on symptoms, age and the like, in the case of oral administration, the dosage of olmesartan medxomil is typically from 5 mg to 80 mg, preferably 10 to 40mg per day, the dosage of amlodipine or a pharmacologically acceptable salt thereof is typically equivalent to from 2.5 mg to 20 mg, preferably 5 to 10 mg per day of amlodipine, and the dosage of hydrochiorotbiazide or a pharmacologically acceptable salt thereof is typically equivalent to from 5 mg to 50 mg, preferably 12.5 to 25 mg per day of hydrochlorothiaZide for a human adult. The dosage can be administered from one to six times, preferably one time, per day depending on the symptoms of the patients.
In addition, the dosing ratio of olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof, which are the active ingredients in the solid dosage form of the present invention, can also be changed over a wide range. For example, the dosing ratio by weight of olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof can be typically within a range of 1:50 to 50:1, preferably within a range of 1:5 to 5:1. Presently, preferred forms are tablets comprising 40/10 mg, 40/5 mg, 20/10 mg, 20/5 mg, 10/10 mg and 10/5 mg of olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof equivalent to said amount of amlodipine, respectively. For the triple combination further comprising hydrochiorothiazide or a pharmacologically acceptable salt thereof, the dosing ratio by weight of olmesartan medoxomil, amlodipine or a pharmacologically acceptable salt thereof and hydrochiorothiaZide or a pharmacologically acceptable salt thereof can be typically within a range of 1:50:1-50 to 50:1-50, preferably within a range of 1:5:1-5 to 5:1:1-5. Presently, preferred forms are tablets comprising 40/10/12.5 mg, 40/5/12.5 mg, 40/10/25 mg, 40/5/25 mg, 20/10/12.5 mg and 20/5/12.5 mg of olmesartan medoxomil, amlodipine or a pharmacologically acceptable salt thereof equivalent to said amount of amlodipine and hydrochlorothia.Zide or a pharmacologically acceptable salt thereof equivalent to said amount of hydrochlorothiaZide, respectively.
The total weight of the solid dosage form containing olmesartan medoxomil and amlodipine or a pharmacologicallY acceptable salt thereof as the sole active agents, containing 40 mg of olmesartan medoxomil amounts to 100 mg to 300mg, preferably to about 200mg. The total weight of the solid dosage form containing olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof as the sole active agents, containing 20 mg of olmesartari medoxomil amounts to 50 mg to 150mg, preferably to about 100mg. The total weight of the triple combination solid dosage form containing olmesartan medoxomil, amlodipine or a pharmacologicallY acceptable salt thereof and hydrochiorothiaZide or a pharmacologically acceptable salt thereof, containing 40 mg of olmesartan medoxomil amounts to 100mg to 400mg, preferably to about 300mg.
The solid dosage form of the present invention is effective for the prophylaxis or treatment of, for example, hypertension or diseases caused by hypertension more specifically, hypertension, heart disease (angina pectoris, myocardial infarction, arrhythmia, cardiac insufficiency or hypercardia), kidney disease (diabetic nephropathy, glomerular nephritis or nephrosclerosis), or cerebrovascular disease (cerebral infarction or cerebral hemorrhage)] and the like.
[Examples]
The present invention will be described in more detail by way of the following examples, but the scope of the present invention is not limited thereto.
Example 1
Composition of a tablet: Olmesartan medoxomil 40.00 mg Amlodipine besylate 13.89 mg Pregelatinized starch 70.00 mg Silicified microcrystalline cellulose 65.31 mg Croscarmellose sodium 10.00 mg Magnesium stearate 0.80 mg Opadrv� II 8.00 mg Total weight 208.00 mg Tablets were prepared according to the composition listed above using the following steps.
The powder mixture was prepared in a tumbling blender by mixing the active ingredients (milled olmesartan medoxomil and amlodipine besylate) with pregelatinized starch, silicified microcrystalline cellulose and croscarmellose sodium.
The powder mixture was then screened, using a screening mill, with a 1.9 mm screen. The screened powder mixture was blended again in a tumbling blender.
Magnesium stearate was added to the powder mix and blended in the tumbling blender to produce the final blend. The final blend was compressed into slightly convex tablets using a rotary press, the size and shape appropriate to the tablet strength.
The coating suspension was prepared by dispersing Opadry� II in purified water. The tablet cores underwent a film-coating procedure using standard coating equipment.
Example 2
Composition of a tablet: Olmesartan medoxomil 40.00 mg Amlodipine besylate 13.89 mg Hydrochiorothiazide 12.50 mg Pregelatinized starch 105.00 mg Silicified microcrystalline cellulose 112.41 mg Croscarmellose sodium 15.00 mg Magnesium stearate 1.20 mg Qpdry�II L0.OOmg Total weight 310.00 mg Tablets were prepared according to the composition listed above using the following steps.
The powder mixture was prepared in a tumbling blender by mixing the active ingredients (milled olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide) with pregelatinized starch, silicified microcrystalline cellulose and croscarmellose sodium.
The powder mixture was then screened, using a screening mill, with a 1.9 mm screen. The screened powder mixture was blended again in a tumbling blender.
Magnesium stearate was added to the powder mix and blended in the tumbling blender to produce the final blend. The final blend was compressed into slightly convex tablets using a rotary press, the size and shape appropriate to the tablet strength.
The coating suspension was prepared by dispersing Opadry� II in purified water. The tablet cores underwent a film-coating procedure using standard coating equipment.
Reference Example 1 (Olmetec� based formulation) Composition of a tablet: Olmesartan medoxomil 40.00 mg Amlodipine besylate 13.89 mg Low-substituted hychoxypropylCellUlOSe 80.00 mg Microcrystalline cellulose 40.00 mg Lactose monohydrate 232.51 mg HydroxypropylcellUlOSe 10.00 mg Magnesium stearate 3.60 mg Qpadry� OY S 38956 12.00 mg Total weight 432.00 mg Tablets were prepared according to the composition listed above using the following steps.
The powder mixture was prepared in a wet high-shear granulator by mixing the active ingredients (milled olmesartan medoxomil, amlodipine besylate) with low-substituted hydroxypropy1CellulO5e microcrystalline cellulose, lactose monohydrate and hydroxypropylcellulOSe and then kneaded with purified water.
The wet granules were screened, using a screening mill, with a 9.5 mm screen, and then dried in a fluid bed dryer.
The dried granules were screened, using a screening mill, with a 1.9 mm screen.
Magnesium stearate was added to the screened granules and blended in the tumbling blender to produce the final blend.
The final blend was compressed into slightly convex tablets using a rotary press, the size and shape appropriate to the tablet strength.
The coating suspension was prepared by dispersing Opadry� OY S 38956 (white) in purified water. The tablet cores underwent a filmcoating procedure using standard coating.
Test Example 1 Storage stability test The tablets of Example 1 to be tested were put into HDPE bottles with desiccant, and the bottles were closed tightly with a HDPE screw. The tablets in the bottles were stored at 40°C under 75% R.H. (the accelerated test) for 3 months.
Impurities derived from degradation of olmesartan medoxornil and amlodipine in the tablets were determined by HPLC (Agilent 1100 systems, Agilent Technologies Co., Ltd.). The results were as follows:
(Table 1)
!:i!01met!!0!�Ex!!Referen!!el As can be seen in Table 1 and Fig. 1, the formulation of Example 1, a formulation of the present invention demonstrated superior stability compared to olmesartan medoxomil and amlodipine formulations commercially available as Olmetec� and Norvasc�, respectively.
Based on the results presented in Table 1 and Fig. 1, a correlation can also be seen between the formation of impurities and the presence or absence of reducing sugars in the formulation. Reference Example 1, which had lactose in the formulation, had a relatively high level of total impurities after three months. In contrast, the formulation of Example I was substantially free of reducing sugars in the formulation and consequently had a significantly lower level of total impurities relative to Reference
Example 1.
Thus, the data in Table 1 and Fig. 1 indicate that the stability of dosage forms comprising olmesartan medoxomil and amlodipine can be improved depending on the presence or absence of reducing sugars in the formulation.
Test Example 2 Dissolution test For dissolution testing of a tablet of Example 1, an EP/USP dissolution tester equipped with a diode array spectrophotometer, suitable for Multicomponent-AflalYSis (MCA) was used.
The key parameters are as follows: Medium: Phosphate buffer solution pH 6.8 +1-0.5 (Jap. Pharm) Volume: 900+/-9 mL Temperature: 37.0 +1-0.5°C Bath type: USP apparatus 2 Stirrer: 50 rpm +1-2 rpm The amounts of olmesartan medoxomil and amlodipine besylate dissolved were determined by MultiComponent-AflatYsiS (MCA) of filtered portions of the solution under test in comparison with respective reference solutions.
(Table 2)
Example 1 -Reference Example I -Dissolution (%) Dissolution (%) 84.0 74.0 As can be seen in Table 2 and Fig. 2, the formulation of Example 1 demonstrated superior dissolution properties for both olmesartan medoxomil and amlodipine besylate compared to the formulation of Reference Example 1.
Test Example 3 Storage stability test The tablets of Example 2 to be tested were put into HDPE bottles with desiccant, and the bottles were closed tightly with a HDPE screw. The tablets in the bottles were stored at 40°C under 75% R.H. (the accelerated test) for 3 months.
Impurities derived from degradation of olmesartan medoxomil, amlodipine and hydrochiorothiazide in the tablets at the end of the 3 month period were determined by HPLC (Agilent 1100 systems, Agilent Technologies Co., Ltd.). The results were as follows:
(Table 3)
2!!0lmete!0!�Ex!1E!2 As can be seen in Table 3, the formulation of Example 2, a triple combination formulation of the present invention demonstrated superior stability compared to olmesartan medoxomil and amlodipine formulations commercially available as Olmetec� and Norvasc�, respectively, with significantly lower levels of RNH-6270 and Jmpurity D even after accelerated testing for 3 months. The triple combination formulation of the present invention showed excellent stability; indeed, it can be seen from the above comparison that the stability was even a little higher than that for the double combination product of the present invention tested in Test Example 1.
Test Example 4 Dissolution test For dissolution testing of a tablet of Example 2, an EPIUSP dissolution tester equipped with a diode array spectrophotometer, suitable for Multi-component-Analysis (MCA) was used.
The key parameters are as follows: Medium: Phosphate buffer solution pH 6.8 +1-0.5 (Jap. Pharm) Volume: 900 +1-9 mL Temperature: 37.0 +1-0.5°C Bath type: USP apparatus 2 Stirrer: 50 rpm +1-2 rpm The amounts of olmesartan medoxomil, amlodipine besylate and hydrochlorothiaZide dissolved were determined by Multi-Component-AnalYsis (MCA) of filtered portions of the solution under test in comparison with respective reference solutions. The results from Test Example 2 above are included for comparison.
(Table 4)
Reference Example 1 Example 2 Olmesartan medoxomil 74.0 84.0 82.0 89.4 91.7 As can be seen in Table 4, the formulation of Example 2 demonstrated excellent dissolution properties for olmesartan medoxomil, amlodipine besylate and hydrochiorothiaZide.
On the basis of the above experiments, it can be readily determined that both the quality and the stability of tablets of Examples 1 and 2 prepared according to the present invention are fully satisfactory.
[Industrial Applicability
According to the present invention, a stable solid dosage form comprising olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof, and comprising hydrochiorothiazide is obtained.
Claims (13)
- CLAIMS for divisional: 1. A pharmaceutical composition comprising olmesartan medoxomil, amlodipine or a pharmacologically acceptable salt thereof and hydrochlorothiazide or a pharmacologically acceptable salt thereof.
- 2. A pharmaceutical composition according to claim 1, wherein the composition is a solid dosage form.
- 3. A pharmaceutical composition according to claim 1 or claim 2, wherein the composition has less than 7.3 % concentration (w/w) of total impurities.
- 4. A pharmaceutical composition according to any one of claims 1 to 3, wherein the composition has less than 5.1 % concentration (w/w) of total impurities.
- 5. A pharmaceutical composition according to any one of claims 1 to 4, wherein the composition has less than 2.5 % concentration (w/w) of 4-(1-hydroxy-1- methylethyl)-2-prOPyl 1 -[2' -(1 Htetrazol5yl)biPheflY14YUmethYh14 H-imidazol-5-carboxylic acid (RINH-6270).
- 6. A pharmaceutical composition according to any one of claims ito 4, wherein the composition has less than 0.4 % concentration (wlw) of 3-etbyl-5-methYl-2-[(2 ,5 -dicarboxylate (Impurity D).
- 7. A pharmaceutical composition according to any one of claims 1 to 6 wherein the amiodipine is present in the form of its besylate salt.
- 8. A pharmaceutical composition according to any one of claims 1 to 7, wherein the composition is a solid dosage form that comprises a tablet.
- 9. A pharmaceutical composition according to any one of claims 1 to 8, comprising to 40 mg of olmesartan medoxomil.
- 10. A pharmaceutical composition according to any one of claims 1 to 9, comprising to 10 mg of amlodipine or a pharmacologically acceptable salt of amlodipine equivalent to 5 to 10 mg of amlodipine.
- 11. A pharmaceutical composition according to any one of claims 1 to 10, comprising 12.5 to 25 mg of hydrochlorothia.Zide or a pharmacologically acceptable salt of hydrochiorothiazide equivalent to 12.5 to 25 mg of hydrochlorothiazide.
- 12. Use of a pharmaceutical composition according to any one of claims 1 to 11 in the manufacture of a medicament for the treatment or prophylaxis of hypertension.
- 13. A pharmaceutical composition according to any one of claims 1 to 11 for use in the treatment or prophylaxis of hypertension.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84509006P | 2006-09-15 | 2006-09-15 | |
| GB0903844A GB2454620B (en) | 2006-09-15 | 2007-10-12 | Solid dosage form of olmesartan medoxomil and amlodipine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201018110D0 GB201018110D0 (en) | 2010-12-08 |
| GB2471970A true GB2471970A (en) | 2011-01-19 |
Family
ID=43413570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1018110A Withdrawn GB2471970A (en) | 2006-09-15 | 2007-10-12 | Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2471970A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114609289B (en) * | 2022-02-24 | 2023-11-14 | 云南龙津康佑生物医药有限公司 | Method for detecting impurities in olmesartan medoxomil amlodipine compound preparation |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003097045A1 (en) * | 2002-05-17 | 2003-11-27 | Novartis Ag | Combination of organic compounds |
| US20040198789A1 (en) * | 2003-02-28 | 2004-10-07 | Recordati Ireland Limited | Lercanidipine/ARB/diuretic therapeutic combinations |
| WO2005070463A2 (en) * | 2004-01-12 | 2005-08-04 | Sepracor, Inc. | Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use |
| WO2006029057A1 (en) * | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Purification of olmesartan medoxomil |
| WO2006059217A1 (en) * | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
-
2007
- 2007-10-12 GB GB1018110A patent/GB2471970A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003097045A1 (en) * | 2002-05-17 | 2003-11-27 | Novartis Ag | Combination of organic compounds |
| US20040198789A1 (en) * | 2003-02-28 | 2004-10-07 | Recordati Ireland Limited | Lercanidipine/ARB/diuretic therapeutic combinations |
| WO2005070463A2 (en) * | 2004-01-12 | 2005-08-04 | Sepracor, Inc. | Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use |
| WO2006029057A1 (en) * | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Purification of olmesartan medoxomil |
| WO2006059217A1 (en) * | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
Non-Patent Citations (2)
| Title |
|---|
| Hypertension, vol. 36(3), 2000, pages 454-460 * |
| Journal of Clinical Hypertension, vol. 6(4), 2004, pages 168-174 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201018110D0 (en) | 2010-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007297333B2 (en) | Solid dosage form of olmesartan medoxomil and amlodipine | |
| JP5554699B2 (en) | Improving dissolution properties of formulations containing olmesartan medoxomil | |
| TWI586353B (en) | Pharmaceutical preparations containing calcium antagonists and angiotensin II receptor antagonists | |
| WO2018062685A1 (en) | Composite formed into single layer, comprising candesartan and amlodipine | |
| EP1673107B1 (en) | Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker | |
| KR20090065510A (en) | Solid dosage form of olmesartan medoxomil and amlodipine | |
| US20200289523A1 (en) | Fixed dosed pharmaceutical composition comprising amiodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension | |
| JP5241511B2 (en) | Pharmaceutical composition with improved dissolution | |
| CN102836161A (en) | Medicament compound preparation formed by mixing olmesartan medoxomil with benzene sulfonic acid amlodipine and hydrochlorothiazide | |
| US20110305757A1 (en) | New pharmaceutical combinations | |
| TWI674907B (en) | A combination formulation comprising hmg-coa reductase inhibitor and calcium channel blocker | |
| SG190326A1 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof | |
| GB2471970A (en) | Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide | |
| KR101806004B1 (en) | A pharmaceutical composition comprising candesartan and amlodipine | |
| EP4079296A1 (en) | A bilayer tablet formulation comprising amorphous dapagliflozin and metformin | |
| JP2022097443A (en) | Orally disintegrating tablet containing bilastine | |
| WO2022132067A1 (en) | Stable bilayer tablet compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |